Supporting oncology professionals through education

The content on this site is intended for healthcare professionals only

Videos [2379]

Using bioinformatics and genomics to treat AML

Prof Torsten Haferlach - MLL Münchner Leukämielabor GmbH, Munich, Germany

Using bioinformatics and genomics to treat AML ( Prof Torsten Haferlach - MLL Münchner Leukämielabor GmbH, Munich, Germany )

The changing landscape of AML

Prof Torsten Haferlach - MLL Münchner Leukämielabor GmbH, Munich, Germany

The changing landscape of AML ( Prof Torsten Haferlach - MLL Münchner Leukämielabor GmbH, Munich, Germany )

CLL14: A chemotherapy-free regimen of venetoclax plus obinutuzumab for CLL

Dr Othman Al-Sawaf - Univesity of Cologne, Cologne, Germany

CLL14: A chemotherapy-free regimen of venetoclax plus obinutuzumab for CLL ( Dr Othman Al-Sawaf - Univesity of Cologne, Cologne, Germany )

Novel methods of drug testing and biopsy in India

Prof Govind Babu - Kidwai Memorial Institute of Oncology, Bengaluru, India

Novel methods of drug testing and biopsy in India ( Prof Govind Babu - Kidwai Memorial Institute of Oncology, Bengaluru, India )

Comment: Chemotherapy for frail and elderly patients with advanced...

Prof Heinz-Josef Lenz - USC Norris Comprehensive Cancer Center, Los Angeles, USA

Comment: Chemotherapy for frail and elderly patients with advanced gastroesophageal cancer ( Prof Heinz-Josef Lenz - USC Norris Comprehensive Cancer Center, Los Angeles, USA )

Comment: Laparoscopic versus open resection for colorectal liver metastases

Prof Heinz-Josef Lenz - USC Norris Comprehensive Cancer Center, Los Angeles, USA

Comment: Laparoscopic versus open resection for colorectal liver metastases ( Prof Heinz-Josef Lenz - USC Norris Comprehensive Cancer Center, Los Angeles, USA )

ASCO 2019 and vision for cancer control

Dr Eduardo Cazap - Editor-in-Chief, ecancer

ASCO 2019 and vision for cancer control ( Dr Eduardo Cazap - Editor-in-Chief, ecancer )

Guiding treatment decisions through the use of molecular profiling in breast...

Dr Harold Burstein - Dana-Farber Cancer Institute, Boston, USA

Guiding treatment decisions through the use of molecular profiling in breast cancer ( Dr Harold Burstein - Dana-Farber Cancer Institute, Boston, USA )

Managing metastatic breast cancer and beyond using PARP inhibitors

Dr Harold Burstein - Dana-Farber Cancer Institute, Boston, USA

Managing metastatic breast cancer and beyond using PARP inhibitors ( Dr Harold Burstein - Dana-Farber Cancer Institute, Boston, USA )

Updates in metastatic and early-stage breast cancer

Dr Harold Burstein - Dana-Farber Cancer Institute, Boston, USA

Updates in metastatic and early-stage breast cancer ( Dr Harold Burstein - Dana-Farber Cancer Institute, Boston, USA )

PARP inhibitors in metastatic breast cancer: Where are we now?

Prof Nadia Harbeck - Klinikum der Universität München, Munich, Germany

PARP inhibitors in metastatic breast cancer: Where are we now? ( Prof Nadia Harbeck - Klinikum der Universität München, Munich, Germany )

ADAPTCycle: Adjuvant personalised therapy comparing endocrine therapy plus...

Prof Nadia Harbeck - Klinikum der Universität München, Munich, Germany

ADAPTCycle: Adjuvant personalised therapy comparing endocrine therapy plus ribociclib versus chemotherapy in early breast cancer ( Prof Nadia Harbeck - Klinikum der Universität München, Munich, Germany )

More from ecancer